Stereotaxis Enters $50M Sales Agreement with Roth Capital

Stereotaxis ( (STXS) ) has shared an announcement.

On August 29, 2025, Stereotaxis, Inc. entered into a Sales Agreement with Roth Capital Partners, LLC to sell up to $50 million in common stock. The proceeds are intended for working capital, research and development, and accelerating the commercialization of their innovation pipeline. This agreement allows Stereotaxis to offer shares through Roth Capital as sales agent or principal, with sales made as at-the-market offerings or through privately negotiated transactions. The arrangement provides flexibility in raising capital based on market conditions and the company’s needs, potentially impacting its operational capabilities and market positioning.

The most recent analyst rating on (STXS) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Stereotaxis stock, see the STXS Stock Forecast page.

Spark’s Take on STXS Stock

According to Spark, TipRanks’ AI Analyst, STXS is a Neutral.

Stereotaxis’ stock score is driven by strong technical momentum and positive earnings call highlights, including significant revenue growth and strategic product launches. However, ongoing profitability challenges and a negative valuation score due to a negative P/E ratio and lack of dividend yield temper the overall score.

To see Spark’s full report on STXS stock, click here.

More about Stereotaxis

Stereotaxis, Inc. operates in the medical technology industry, focusing on the development and commercialization of robotic systems and instruments for minimally invasive surgery. The company aims to innovate in the field of interventional medicine, enhancing the precision and safety of surgical procedures.

Average Trading Volume: 485,386

Technical Sentiment Signal: Buy

Current Market Cap: $254.7M

For detailed information about STXS stock, go to TipRanks’ Stock Analysis page.